INVESTORS You heard it here first. ALL CORPORATE INVESTORS Our news BRINGING YOU THE LATEST! Investors Phase 3 data of mdc-IRM first product based on MedinCell’s technology, shows significant improvements in patients with schizophrenia Corporate - Investors 15 November 2021 Phase 3 data of mdc-IRM, first product based on MedinCell’s […] Read full story MedinCell: mdc-IRM’s Phase 3 data to be presented for the first time by Teva at Psych Congress 2021 Corporate - Investors 21 October 2021 Read full story Teva and MedinCell Announce FDA Acceptance of New Drug Application for TV-46000/mdc-IRM as a Treatment for Patients with Schizophrenia Corporate - Investors 31 August 2021 Read full story Participation terms in the MedinCell Combined General Meeting Corporate - Investors 4 August 2021 Read full story MedinCell: mdc-CWM clinical phase 3 will start in 2021 Corporate - Investors 25 March 2021 Read full story Covid-19: MedinCell publishes an extensive Ivermectin Safety Expert Analysis Corporate - Investors 5 March 2021 Read full story Covid-19: MedinCell presents positive first results from the clinical trial aiming at validating the safety of continuous administration of Ivermectin Corporate - Investors 17 December 2020 Read full story MedinCell publishes its first-half 2020/2021 financial results (April – September 2020): operating expenses and portfolio development in line with expectations Investors 9 December 2020 Read full story Posts navigation 1 2 … 5 Subject Partnership Development Scientific collaboration Press and communication Administration People Stay tuned, leave your email I read and accept the privacy policy HOME WHO ARE WE PRODUCT IMPACT NETWORK NEWS INVESTORS CAREERS Copyright © 2021 MedinCell. All rights reserved. | Legal | Privacy | #BetterMedicineForAll | #ImpactHealth | WHO ARE WE PRODUCT IMPACT NETWORK NEWS INVESTORS CAREERS